BrainStorm Cell Therapeutics Reports Receives $495.33K Grant From National Multiple Sclerosis Society To Advance Co.'s Phase 2 Open-Label, Multicenter Clinical Trial Of Repeated Intrathecal Administration Of NurOwn
Benzinga Newsdesk